The results of the Scandinavian Prostate Cancer Group-7 trial highlight the benefit of adding radiotherapy to endocrine treatment in men with unfavourable-risk prostate cancer. Further scientific advances in radiation technologies, pharmacotherapy and imaging modalities raise questions about the future of radical prostatectomy in this patient group.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration
Cancer Cell International Open Access 26 April 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fosså, S. D. et al. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.03.021 (2016).
Roach, M. 3rd & Thomas, K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J. Natl Cancer Inst. Monogr. 2012, 221–229 (2012).
Iversen, P. et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int. 105, 1074–1081 (2010).
Eifler, J. B. et al. Causes of death after radical prostatectomy at a large tertiary center. J. Urol. 188, 798–801 (2012).
Roach, M. 3rd, Ceron Lizarraga, T. L. & Lazar, A. A. Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence? Int. J. Radiat. Oncol. Biol. Phys. 93, 1064–1070 (2015).
Viani, G. A., Bernardes da Silva, L. G. & Stefano, E. J. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int. J. Radiat. Oncol. Biol. Phys. 83, e519–e524 (2012).
Kunath, F. et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database Syst. Rev. 6, CD009266 (2014).
Penson, D. F. et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2015.64.9285 (2016).
King, C. R. et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother. Oncol. 109, 217–221 (2013).
Lennernäs, B. et al. Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: a Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol. 54, 875–881 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Roach, M. Combining endocrine treatment and radiotherapy: a bright future. Nat Rev Urol 13, 373–374 (2016). https://doi.org/10.1038/nrurol.2016.100
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.100
This article is cited by
-
Silencing of PSMC2 inhibits development and metastasis of prostate cancer through regulating proliferation, apoptosis and migration
Cancer Cell International (2021)
